

HPAP _196_ Donor Summary



HPAP	196	UNOS	
Recovery OPO	Gift of Life Donor Program	Allocation Via	UPENN <input checked="" type="checkbox"/> nPOD <input type="checkbox"/>
Age (years)	44	DCD	YES <input checked="" type="checkbox"/> NO <input type="checkbox"/> DCD Progressed to Brain Death
Race	Caucasian	DBD	YES <input checked="" type="checkbox"/> NO <input type="checkbox"/>
Sex	M <input checked="" type="checkbox"/> F <input type="checkbox"/>	Admission to Cross Clamp	154 Hours 05 Mins.
ABO (Rh)	O Positive	Cross Clamp Time	08/15/2025 20:05 (EDT)
BMI (Kg/m²)	26.93	Cold Ischemia Time*	2 Hours 20 Mins.
Weight (kg)	78		
Height (cm)	170.18		
Cause of Death	Head Trauma	Preservation Solution	UW <input checked="" type="checkbox"/> HTK <input type="checkbox"/>
Mechanism of Injury	Blunt Injury	Organs Recovered	Heart <input checked="" type="checkbox"/> Kidney <input checked="" type="checkbox"/> Lung <input type="checkbox"/> Pancreas <input checked="" type="checkbox"/> Liver <input checked="" type="checkbox"/> Intestine <input type="checkbox"/>
Cardiac Arrest/Downtime	Yes <input type="checkbox"/> No <input checked="" type="checkbox"/>	Intraoperative time lapse from liver to pancreas removal from the peritoneal cavity:	<input type="text"/> Hours <input type="text"/> Mins. NA
CPR / Time	Yes <input type="checkbox"/> No <input checked="" type="checkbox"/>	Organs Discarded	Heart <input type="checkbox"/> Kidney <input type="checkbox"/> Lung <input type="checkbox"/> Pancreas <input type="checkbox"/> Liver <input type="checkbox"/> Intestine <input type="checkbox"/>
Total Est. Downtime	-----	Blood Culture	NA
Date /Time of Admission	08/09/2025 10:00 (EDT)	PHS High Risk	YES <input type="checkbox"/> NO <input checked="" type="checkbox"/>
		Acute Lung Injury	Bibasilar opacities (L>R), likely atelectasis/aspiration; stable with trace effusions, no progressive consolidation.

*Cold Ischemia time is calculated from time of cross clamp to start of enzyme perfusion for islet isolation.

HPAP _196_ Donor Summary



Medical History:

		Duration	Medications	Compliance
Type of Diabetes	No Hx of Diabetes	----	----	----
History of cancer	----	----	----	----
CAD	----	----	----	----
Hypertension	----	----	----	----
Hyperlipidemia	----	----	----	----
Autoimmune disease	----	----	----	----
Family History	CAD <input type="checkbox"/>	Diabetes <input type="checkbox"/>	Auto immune disease <input type="checkbox"/>	Others:
Surgical History:	None			
Comments:	Medical Hx: None Social Hx: Smokes ½ ppd; marijuana x3 yrs; intermittent mushroom use, last use 4 yrs ago. EtOH Hx: Beer/White Claw/Twisted Tea, ~25 (16 oz) cans daily x7 yrs.			

Hemodynamic Profile

Average BP During Hospitalization (mmHg)	148/79	
Average Low BP During Hospitalization	77/48	Duration: 1-15 min.
Average BP in OR (mmHg)	NA	
Average Low BP in OR (mmHg)	NA	Duration: NA
Average HR in OR (bpm)	NA	
ABG-pH range	7.14 - 7.47	

INTERVENTION

Blood Products/Meds Transfused Before Organ Recovery

Product	Amount (ml)	Units	Total (ml)
Fresh Frozen Plasma	----	----	----
PRBCs	360-361	3	1081
Platelets	----	----	----
Norepinephrine (Levophed)	----	Started 152:04 before organ recovery	
Vasopressin	----	0.03 units/hr started 130:25 hrs before organ recovery	
Neo-Synephrine	----	----	----
Epinephrine	----	----	----
Phenylephrine	----	----	----
Dopamine	----	----	----



HPAP_196_ Donor Summary

Blood Products/Meds Transfused Intraoperative

Product	Amount (ml)	Units	Total (ml)
Fresh Frozen Plasma	NA	NA	NA
PRBCs	NA	NA	NA
Platelets	NA	NA	NA
Norepinephrine (Levophed)	NA	NA	NA
Vasopressin	NA	NA	NA
Neo-Synephrine (phenylephrine)	NA	NA	NA
Epinephrine	NA	NA	NA
Dopamine	NA	NA	NA
Heparin	NA	NA	NA

Initial Autoantibody Screening (nPOD): ELISA

Not performed for HPAP-T2D program

GAD-65	IA-2
ND	ND

Confirmatory results: Radioimmuno Assay (RIA)

	GAD-65 (unit/ml)	IA-2 (unit/ml)	Insulin AAB (unit/ml)	ZnT8 (unit/ml)
Results	0	0	-0.007	-0.007
Cut-off values	20	5	0.01	0.02

*Sample obtained at time of organ recovery.

	C-peptide (ng/ml)	Proinsulin
Results	3.56	ND

*Sample obtained at time of organ recovery.

HLA (OPO)*

Class 1	A	25	33	Class II	DR	1	13
	B	65	58		DR51	N-Negative	N-Negative
	C	08	07		DR52	N-Negative	52
	Bw4	Positive			DR53	N-Negative	N-Negative
	Bw6	Positive			DQB1	5	6
			DQA1		01	01	
			DPB1		04:01	34:01	
		DPA1	01	01			
Comment:							

HPAP _196_ Donor Summary



Confirmatory HLA (UPENN)*

Not performed for HPAP-T2D program

Class 1	A			Class II	DRB1		
	B				DRB3		
	C				DRB4		
					DRB5		
					DQB1		
					DQA1		
					DPB1		
					DPA1		

*HLA typing performed using NGS

Infectious Disease Serology

Test	Result	Hemo/Plasma Dilution Status	
		Qualified	Non-Qualified
EBV IgG	Positive	✓	-
EBV IgM	Negative	✓	-
CMV IgM	Negative	✓	-
CMV IgG	Negative	✓	-
HBcAb	Non- Reactive	✓	-
HBsAg	Non- Reactive	✓	-
HCV Ab	Non- Reactive	✓	-
HIV I/II	ND	-	-
HIV Ag/Ab Combo	Non- Reactive	✓	-
Syphilis	Non- Reactive	✓	-
Procleix Ultrio	ND	-	-
Ultrio HBV	Non- Reactive	✓	-
Ultrio HCV	Non- Reactive	✓	-
Ultrio HIV	Non- Reactive	✓	-
Toxoplasma Ab	Negative	✓	-
SARS-CoV-2	Negative	✓	-

HPAP _196_ Donor Summary



Laboratory Panel

	Initial	Peak	Terminal
Na (mEq/L) (135-145)	130	167	133
Creatinine (<1.5)	0.82	1.31	0.81
Glucose (mg/dL) (60-150)	198	216	147
HbA1C%	5.3	-----	-----
Total bilirubin (0-1.0)	0.7	1.5	0.6
SGOT (AST) (0-40)	337	337	51
SGPT (ALT) (5-35)	175	175	20
Alkaline phosphatase (45-110)	120	152	115
Serum Amylase (23-851)	57 (08/13/2025 17:55)	57	43
Serum Lipase (0-80)	18 (08/13/2025 17:55)	41	30
WBC (THO/uL) (4.5-11.0)	6.7	6.7	5.6
Hgb (g/dL) (12-16)	13.8	13.8	8.6
Platelets (THO/uL) (150-350)	203	203	110
INR (<2.0)	1	1.2	1.2

Urinalysis

	1 st	2 nd & 3 rd	4 th & 5 th	6 th
Glucose	Negative	Negative	Positive	Negative

Medications During Hospitalization

Steroids**	NA
Diuretics	NA
T3 Protocol	NA
T4 Protocol*	NA
Insulin**	NA
Antihypertensive	NA
Vasodilators	NA
DDAVP**	NA
Total parenteral nutrition	NA
Other	Propofol, Cefazolin 1000mg Specify

*T4 protocol: Levothyroxine, (20 mcgs), Solumedrol (2 gms,) Dextrose 50%, (1 amp), Regular Insulin (20u), Vasopressin (1 unit)

Mi Z, Novitzky D, Collins JF, Cooper D KC. The optimal hormonal replacement modality selection for multiple organ procurement from brain-dead organ donors. Clinical Epidemiology 2015;7 17-27.

** Excluding T4 Protocol